William Shingleton

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Leukocyte immunotherapies have made a great progress and hold much promise in the treatment of cancer. Specifically, in the case of B cell malignancies (such as Acute Lymphoblastic Leukemia, or ALL), CAR (chi-meric antigen receptor) and TCR (T cell receptor) cell therapies have demonstrated encouraging clinical results. As we begin to look into targeting(More)
  • 1